Advertisement
ANIK vs INFU
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIK is a StrongBuy and INFU is a Hold.
ANIK's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ANIK turned positive on October 13, 2026. Looking at past instances where ANIK's MACD turned positive, the stock continued to rise in 37 of 52 cases over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANIK's RSI Oscillator exited the oversold zone, 15 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 47%.
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on ANIK as a result. In 77 of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
ANIK moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIK advanced for three days, in 167 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
ANIK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for ANIK crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for ANIK entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.056) is normal, around the industry mean (10.407). P/E Ratio (-78.111) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (2.177) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (2.401) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ANIK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANIK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
INFU in +6.19% Uptrend, advancing for three consecutive days on October 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INFU advanced for three days, in 173 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for INFU just turned positive on October 20, 2026. Looking at past instances where INFU's MACD turned positive, the stock continued to rise in 38 of 61 cases over the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 89 of 139 cases where INFU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for INFU moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 20 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INFU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
INFU broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. INFU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 56 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.731) is normal, around the industry mean (2.923). P/E Ratio (33.452) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.180) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (1.817) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INFU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
ANIK | INFU | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 94 | |
SMR RATING 1..100 | 91 | 56 | |
PRICE GROWTH RATING 1..100 | 36 | 36 | |
P/E GROWTH RATING 1..100 | 100 | 60 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANIK's Valuation (10) in the Pharmaceuticals Other industry is significantly better than the same rating for INFU (81) in the Medical Specialties industry. This means that ANIK’s stock grew significantly faster than INFU’s over the last 12 months.
INFU's Profit vs Risk Rating (94) in the Medical Specialties industry is in the same range as ANIK (100) in the Pharmaceuticals Other industry. This means that INFU’s stock grew similarly to ANIK’s over the last 12 months.
INFU's SMR Rating (56) in the Medical Specialties industry is somewhat better than the same rating for ANIK (91) in the Pharmaceuticals Other industry. This means that INFU’s stock grew somewhat faster than ANIK’s over the last 12 months.
INFU's Price Growth Rating (36) in the Medical Specialties industry is in the same range as ANIK (36) in the Pharmaceuticals Other industry. This means that INFU’s stock grew similarly to ANIK’s over the last 12 months.
INFU's P/E Growth Rating (60) in the Medical Specialties industry is somewhat better than the same rating for ANIK (100) in the Pharmaceuticals Other industry. This means that INFU’s stock grew somewhat faster than ANIK’s over the last 12 months.
| ANIK | INFU | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 47% | 2 days ago 87% |
| Stochastic ODDS (%) | 1 day ago 69% | 2 days ago 86% |
| Momentum ODDS (%) | 1 day ago 68% | N/A |
| MACD ODDS (%) | 1 day ago 71% | 2 days ago 62% |
| TrendWeek ODDS (%) | 1 day ago 68% | 2 days ago 69% |
| TrendMonth ODDS (%) | 1 day ago 73% | 2 days ago 74% |
| Advances ODDS (%) | 1 day ago 63% | 3 days ago 66% |
| Declines ODDS (%) | 21 days ago 68% | 22 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 63% | 2 days ago 83% |
| Aroon ODDS (%) | 1 day ago 73% | 2 days ago 64% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANIK’s FA Score shows that 1 FA rating(s) are green while INFU’s FA Score has 0 green FA rating(s).
- ANIK’s FA Score: 1 green, 4 red.
- INFU’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANIK’s TA Score shows that 5 TA indicator(s) are bullish while INFU’s TA Score has 3 bullish TA indicator(s).
- ANIK’s TA Score: 5 bullish, 5 bearish.
- INFU’s TA Score: 3 bullish, 4 bearish.
Price Growth
ANIK (@Pharmaceuticals: Generic) experienced а +1.73% price change this week, while INFU (@Medical/Nursing Services) price change was +3.31% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
Reported Earning Dates
ANIK is expected to report earnings on Nov 04, 2026.
INFU is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
ANIK and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANIK has been loosely correlated with RVTY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIK jumps, then RVTY could also see price increases.
| Ticker / NAME | Correlation To ANIK | 1D Price Change % | ||
|---|---|---|---|---|
| ANIK | 100% | +2.38% | ||
| RVTY - ANIK | 39% Loosely correlated | +0.48% | ||
| ORGO - ANIK | 36% Loosely correlated | +3.90% | ||
| ACRS - ANIK | 34% Loosely correlated | +0.52% | ||
| FLGT - ANIK | 32% Poorly correlated | -0.70% | ||
| INFU - ANIK | 32% Poorly correlated | +0.64% | ||
More | ||||
INFU and
Correlation & Price change
A.I.dvisor indicates that over the last year, INFU has been loosely correlated with AMIX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INFU jumps, then AMIX could also see price increases.
| Ticker / NAME | Correlation To INFU | 1D Price Change % | ||
|---|---|---|---|---|
| INFU | 100% | -1.26% | ||
| AMIX - INFU | 43% Loosely correlated | -1.53% | ||
| VREX - INFU | 42% Loosely correlated | +0.11% | ||
| ICUI - INFU | 39% Loosely correlated | -0.15% | ||
| BFLY - INFU | 38% Loosely correlated | -2.87% | ||
| ANIK - INFU | 33% Loosely correlated | +0.78% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SGRT | 33.42 | 0.84 | +2.59% |
| SMART Earnings Growth 30 ETF (SGRT) | |||
| LOUP | 82.13 | 1.87 | +2.33% |
| Innovator Deepwater Frontier Tech ETF (LOUP) | |||
| NIE | 24.93 | 0.09 | +0.36% |
| Virtus Equity & Convertible Income Fund | |||
| IQLT | 50.54 | 0.17 | +0.34% |
| iShares MSCI Intl Quality Factor ETF (IQLT) | |||
| SDCP | 25.08 | N/A | N/A |
| Virtus Newfleet Short Duration Core Plus Bond ETF (SDCP) | |||